Adenovirus formulations
US7456009B2 · kind B2 · utility
11Cited by
7References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 3, 2005 |
| Grant date | Nov 25, 2008 |
| Priority date | — |
| Expiry date | Mar 3, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10351
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to viral formulations and related pharmaceutical products for use in gene therapy and/or vaccine applications. Especially preferred viral formulations disclosed herein are liquid adenovirus formulations, which show improved stability when stored in about the 2-8° C. range while also being compatible with parenteral administration. These formulations comprise a buffer, a sugar, a salt, a divalent cation, a non-ionic detergent, as well as a free radical scavenger and/or a chelating agent to inhibit free radical oxidation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.